NP90726l Tildrakizumab (Ilumetri®)

{
  "awards": [
    {
      "id": "NP90726l",
      "relatedLots": [
        "1"
      ],
      "suppliers": [
        {
          "id": "org-2",
          "name": "Almirall Ltd"
        }
      ]
    }
  ],
  "buyer": {
    "id": "org-1",
    "name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)"
  },
  "contracts": [
    {
      "awardID": "NP90726l",
      "dateSigned": "2026-03-16T00:00:00Z",
      "id": "NP90726l",
      "status": "active",
      "value": {
        "amount": 844250.0,
        "currency": "GBP"
      }
    }
  ],
  "date": "2026-03-17T00:00:00Z",
  "description": "The estimated value of the Framework Agreement referred to in Section V.2.4 covers the eleven (11) month contract duration and the two (2) x twelve (12) month extension periods of the Framework Agreement.\r\n NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at http://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=823248.\r\n (SC Ref:823248)",
  "id": "rls-1-MAR551912",
  "initiationType": "tender",
  "language": "EN",
  "links": [
    {
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000823248",
      "rel": "canonical"
    }
  ],
  "ocid": "ocds-r6ebe6-0000823248",
  "parties": [
    {
      "address": {
        "locality": "Edinburgh",
        "postalCode": "EH12 9EB",
        "region": "UKM",
        "streetAddress": "1 South Gyle Crescent"
      },
      "contactPoint": {
        "email": "michelle.semple3@nhs.scot",
        "telephone": "+44 1312756000",
        "url": "http://"
      },
      "details": {
        "classifications": [
          {
            "id": "Body governed by public law",
            "scheme": "TED_CA_TYPE"
          },
          {
            "description": "Health",
            "id": "07",
            "scheme": "COFOG"
          }
        ],
        "url": "http://www.nss.nhs.scot/browse/procurement-and-logistics"
      },
      "id": "org-1",
      "identifier": {
        "legalName": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)"
      },
      "name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "locality": "Uxbridge",
        "postalCode": "UB81QQ",
        "region": "UK",
        "streetAddress": "Harman House, 1 George St"
      },
      "contactPoint": {
        "telephone": "+44 7717313230"
      },
      "details": {
        "scale": "large",
        "url": "http://"
      },
      "id": "org-2",
      "identifier": {
        "legalName": "Almirall Ltd"
      },
      "name": "Almirall Ltd",
      "roles": [
        "supplier"
      ]
    },
    {
      "address": {
        "locality": "Edinburgh",
        "postalCode": "EH1 1LB",
        "streetAddress": "27 Chambers Street"
      },
      "contactPoint": {
        "email": "edinburgh@scotcourts.gov.uk",
        "telephone": "+44 1312252525",
        "url": "http://"
      },
      "id": "org-3",
      "identifier": {
        "legalName": "Sheriff Court House"
      },
      "name": "Sheriff Court House",
      "roles": [
        "reviewBody"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "classification": {
      "id": "33600000",
      "scheme": "CPV"
    },
    "coveredBy": [
      "GPA"
    ],
    "description": "Supply of Tildrakizumab (Ilumetri\u00c2\u00ae) to NHS Scotland.",
    "documents": [
      {
        "description": "Supply of Tildrakizumab (Ilumetri\u00c2\u00ae) to NHS Scotland.",
        "documentType": "awardNotice",
        "format": "text/html",
        "id": "MAR551912",
        "title": "NP90726l Tildrakizumab (Ilumetri\u00c2\u00ae)",
        "url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR551912"
      }
    ],
    "id": "ocds-r6ebe6-0000823248",
    "items": [
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act."
        },
        "id": "1",
        "relatedLot": "1"
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "lots": [
      {
        "description": "Supply of Tildrakizumab (Ilumetri\u00c2\u00ae) to NHS Scotland. The Authority has awarded this framework as a single supplier Framework per line to one (1) Framework Participant.",
        "hasOptions": false,
        "id": "1",
        "status": "complete"
      }
    ],
    "mainProcurementCategory": "goods",
    "procurementMethod": "limited",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "The medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.",
    "procurementMethodRationaleClassifications": [
      {
        "description": "The procurement falls outside the scope of application of the directive",
        "id": "D_OUTSIDE_SCOPE"
      }
    ],
    "reviewDetails": "The notification will incorporate a \u00e2\u0080\u0098standstill period\u00e2\u0080\u0099 of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority proposes to conclude the relevant framework agreement.\r\n The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer.\r\n The bringing of court proceedings against the authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited\r\n to the award of damages",
    "status": "complete",
    "techniques": {
      "hasFrameworkAgreement": true
    },
    "title": "NP90726l Tildrakizumab (Ilumetri\u00c2\u00ae)"
  }
}